Top

Published in:

Open Access 01-12-2023 | Tenofovir | Research

Trust in the provider and accurate self-reported PrEP adherence among adolescent girls and young women in South Africa and Zimbabwe: HPTN 082 study

Authors: Geetha Beauchamp, Deborah Donnell, Sybil Hosek, Peter L. Anderson, Kwun C. G. Chan, Bonnie J. Dye, Nyaradzo Mgodi, Linda-Gail Bekker, Sinead Delany-Moretlwe, Connie Celum

Published in: BMC Women's Health | Issue 1/2023

Abstract

Background

Trust is an important cornerstone of patient-provider communication. Accurate reporting of pre-exposure prophylaxis (PrEP) adherence is vital for providers to determine who needs adherence support, especially adolescent girls and young women (AGYW) disproportionately affected by newly diagnosed HIV.

Methods

This is a secondary analysis of the HPTN 082 open-label PrEP demonstration trial. From 2016–2018, 451 AGYW aged 16–25 years were enrolled in South Africa (Cape Town and Johannesburg) and Zimbabwe (Harare). PrEP was initiated by 427, and 354 (83%) had month three patient-reported adherence responses and intracellular tenofovir diphosphate (TFV-DP) measurements. The patient-reported adherence response to ‘In the past month, how often did you take the tablet?’ was dichotomized as ‘high’ if the response was every day or most days, and ‘low’ if some days or not many days or never. The biomarker marker evidence of adherence in dried blood spots was defined as ‘high’ if TFV-DP ≥ 700, and ‘low’ if < 350 fmol/punch. We used multinomial logistic regression to examine if trust in the PrEP provider was associated with concordance between patient-reported adherence and intracellular tenofovir-diphosphate (TFV-DP).

Results

AGYW who reported trust in their providers were almost four-fold (aOR 3.72, 95% CI 1.20–11.51) more likely to have concordant adherence (high self-reported adherence and high TFV-DP concentrations) compared to discordant non-adherence (high self-reported adherence and low TFV-DP concentrations).

Conclusion

Education and training of providers to build trusting relationships with AGYW may lead to more accurate reporting of PrEP adherence. With accurate reporting, adequate support can be provided to bolster adherence.

Trial registration

ClinicalTrials.gov Identifier: NCT02732730.

UNAIDS. Joint United Nations Programme on HIV/AIDS. UNAIDS data. Geneva. Switzerland UNAIDS. 2020;2020:436.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99. https://doi.org/10.1056/NEJMoa1011205.CrossRefPubMedPubMedCentral

McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60. https://doi.org/10.1016/S0140-6736(15)00056-2.CrossRefPubMedPubMedCentral

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med. 2012;367:399–410. https://doi.org/10.1056/NEJMoa1108524.CrossRefPubMedPubMedCentral

Bekker L-G, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, et al. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. lancet. HIV2018 https://doi.org/10.1016/S2352-3018(17)30156-X.

Myers L, Scientist B, Town C. Rethinking PrEP for adolescent girls and young women. IAPAC 2019.

Gill K, Pidwell T, Dietrich J, Gray G, Bennie T, Kayamba F, et al. A Demonstration Open Label Study to Assess the Acceptability, Safety and Use of Truvada Pre-exposure Prophylaxis in Healthy, HIV Uninfected Adolescents, 15–19 Years of Age. In: International AIDS Society Conference (IAS) on HIV Science. Paris, France: 2017. https://mtnstopshiv.org/sites/default/files/attachments/KATHERINE-IAS2017MTNplenaryfinalKatherine.pdf.

Celum CI, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye ID BJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. 2021https://doi.org/10.1371/journal.pmed.1003670.

Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30:1973–83. https://doi.org/10.1097/QAD.0000000000001145.CrossRefPubMed

10.

Miles to Go - Closing Gaps and Breaking Barriers and Tightening Injustices [Internet]. UNAIDSGlobal AIDS Updat. 2018 https://www.unaids.org/sites/default/files/media_asset/miles-to-go_en.pdf.

11.

WHO. WHO Implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. Module 1: Clinical. Geneva: World Health Organization; 2017 (WHO/HIV/2017.17). Licence: CC BY-NC-SA 3.0 IGO. 2017; https://apps.who.int/iris/bitstream/handle/10665/255889/WHO-HIV-2017.17-eng.pdf?sequence=1&isAllowed=y.

12.

Usitalo A, Leister E, Tassiopoulos K, Allison S, Malee K, Paul ME, et al. RELATIONSHIP BETWEEN VIRAL LOAD AND SELF-REPORT MEASURES OF MEDICATION ADHERENCE AMONG YOUTH WITH PERINATAL HIV INFECTION. AIDS Care2014 [cited 2021 Aug 9];26:107. https://doi.org/10.1080/09540121.2013.802280.

13.

Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45. https://doi.org/10.1007/s10461-006-9078-6.CrossRefPubMedPubMedCentral

14.

van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J. Int. AIDS Soc.2014;17. https://doi.org/10.7448/IAS.17.3.19146.

15.

Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, et al. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr. 2014;66:530–7 http://www.ncbi.nlm.nih.gov/pubmed/24853306.CrossRefPubMedPubMedCentral

16.

Baxi SM, Vittinghoff E, Bacchetti P, Huang Y, Chillag K, Wiegand R, et al. Comparing pharmacologic measures of tenofovir exposure in a U . S . pre-exposure prophylaxis randomized trial. 2018;1-16. https://doi.org/10.1371/journal.pone.0190118.

17.

Goudge J, Gilson L. How can trust be investigated? Drawing lessons from past experience. In: Social Science and Medicine. Pergamon; 2005. page 1439–51. https://doi.org/10.1016/j.socscimed.2004.11.071.

18.

Hall MA, Dugan E, Zheng B, Mishra AK. Trust in Physicians and Medical Institutions: What Is It, Can It Be Measured, and Does It Matter? Milbank Q. 2001;79:613–39 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2751209/.CrossRefPubMedPubMedCentral

19.

Østergaard LR. Trust matters: A narrative literature review of the role of trust in health care systems in sub-Saharan Africa. Glob Public Health. 2015;10:1046–59. https://doi.org/10.1080/17441692.2015.1019538.CrossRefPubMed

20.

Van der Kwaak A, Ferris K, van Kats J, Dieleman M. Performances of sexuality counselling: A framework for provider–client encounters. Patient Educ Couns. 2010;81:338–42. https://doi.org/10.1016/j.pec.2010.10.012.CrossRefPubMed

21.

Pilgrim N, Jani N, Mathur S, Kahabuka C, Saria V, Makyao N, et al. Provider perspectives on PrEP for adolescent girls and young women in Tanzania: The role of provider biases and quality of care. PLoS One. 2018;13(4):e0196280. https://doi.org/10.1371/journal.pone.0196280.CrossRefPubMedPubMedCentral

22.

Barker G. Adolescents, social support and help-seeking behaviour An international literature review and programme consultation with recommendations for action. 2007 https://apps.who.int/iris/bitstream/handle/10665/43778/9789241595711_eng.pdf.

23.

Patton GC, Sawyer SM, Santelli JS, Ross DA, Afifi R, Allen NB, et al. Our future: a Lancet commission on adolescent health and wellbeing. https://doi.org/10.1016/S0140-6736(16)00579-1.

24.

Montgomery ET, Mensch B, Musara P, Hartmann M, Woeber K, Etima J, et al. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants’ Explanations for Dishonesty. AIDS Behav. 2017;21:481–91. https://doi.org/10.1007/s10461-016-1609-1.CrossRefPubMedPubMedCentral

25.

Amico KR, Wallace M, Bekker L-G, Roux S, Atujuna M, Sebastian E, et al. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework. AIDS Behav. 2017;21:1361–75 http://www.ncbi.nlm.nih.gov/pubmed/27317411.CrossRefPubMed

26.

Celum C, Baeten J. PrEP for HIV Prevention: Evidence, Global Scale-up, and Emerging Options. Cell Host Microbe. 2020. https://doi.org/10.1016/j.chom.2020.03.020.CrossRefPubMed

27.

Dollah A, Ongolly F, Ngure K, Odoyo J, Irungu E, Mugwanya K, Morton J, Bukusi E, Mugo N, Beaten J OG. “I just decided to stop:” Understanding PrEP discontinuation among individuals initiating PrEP in HIV care centers in Kenya and its implications for a public health approach to prevention. 4th HIV Research for Prevention Conference (HIVR4P) January 27–28. 2021; https://doi.org/10.1097/QAI.0000000000002625.

28.

Medina-Marino A, Glockner K, Grew E, De Vos L, Olivier D, Klausner J, et al. The role of trust and health literacy in nurse-delivered point-of-care STI testing for pregnant women living with HIV, Tshwane District, South Africa. BMC Public Health2020;20. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189538/.

29.

Van Der Straten A, Montgomery ET, Musara P, Etima J, Naidoo S, Laborde N, et al. Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS. 2015;29:2161–71. https://doi.org/10.1097/QAD.0000000000000801.CrossRefPubMed

30.

Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial | Elsevier Enhanced Reader. https://reader.elsevier.com/reader/sd/pii/S2352301822001953?token=4E3E329315B312CE1345C5D111220A8B5C7ECABE38245DF0913838DA570384BCE22AA9B5EA0391EB9A6F2B915B54A561&originRegion=us-east-1&originCreation=20220913190224.

31.

The HIV Prevention Trials Network | The HIV Prevention Trials Network. https://www.hptn.org/.

32.

Celum C, Mgodi N, Bekker L-G, Hosek S, Donnell D, Anderson P, et al. PrEP use in young African women in HPTN 082: Effect of drug level feedback. 2019. 2019 IAS_082 primary findings_FINAL (hptn.org).

33.

Velloza J, Khoza N, Scorgie F, Chitukuta M, Mutero P, Mutiti K, et al. The influence of HIV‐related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J. Int. AIDS Soc.2020;23. https://onlinelibrary.wiley.com/doi/abs/https://doi.org/10.1002/jia2.25463.

34.

Baron EC, Davies T, Lund C. Validation of the 10-item Centre for Epidemiological Studies Depression Scale (CES-D-10) in Zulu, Xhosa and Afrikaans populations in South Africa. BMC Psychiatry. 2017;17:1–14. https://doi.org/10.1186/s12888-016-1178-x.CrossRef

35.

Velloza J, Hosek S, Donnell D, Anderson PL, Chirenje M, Mgodi N, et al. Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on HIV pre‐exposure prophylaxis adherence among adolescent girls in the HPTN 082 randomized controlled trial. J. Int. AIDS Soc.2021;24 https://onlinelibrary.wiley.com/doi/https://doi.org/10.1002/jia2.25731.

36.

Stringer EM, Sinkala M, Kumwenda R, Chapman V, Mwale A, Vermund SH, et al. Personal Risk Perception, HIV Knowledge and Risk Avoidance Behavior, and Their Relationships to Actual HIV Serostatus in an Urban African Obstetric Population. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745978/.

37.

Anderson PL, Liu AY, Castillo-mancilla JR, Gardner EM, Seifert SM, Mchugh C, et al. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. the DOT-DBS Study. 2018;62:1–13. https://doi.org/10.1128/AAC.01710-17.CrossRef

38.

Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: A cohort study. Lancet Infect Dis. 2014;14:820–9. https://doi.org/10.1016/S1473-3099(14)70847-3.CrossRefPubMedPubMedCentral

39.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med. 2012;367:411–22. https://doi.org/10.1056/NEJMoa1202614.CrossRefPubMedPubMedCentral

40.

Kim MH, Mazenga AC, Yu X, Ahmed S, Paul ME, Kazembe PN, et al. High self-reported non-adherence to antiretroviral therapy amongst adolescents living with HIV in Malawi: Barriers and associated factors. J Int AIDS Soc. 2017;20:1–12. https://doi.org/10.7448/IAS.20.1.21437.CrossRef

41.

Koss CA, Charlebois ED, Ayieko J, Kwarisiima D, Kabami J, Balzer LB, et al. Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study. Lancet HIV. 2020;7:e249–61. https://doi.org/10.1016/S2352-3018(19)30433-3.CrossRefPubMedPubMedCentral

42.

Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J, et al. Participants’ explanations for nonadherence in the FEM-PrEP clinical trial. J Acquir Immune Defic Syndr. 2016;71:452–61. https://doi.org/10.1097/QAI.0000000000000880.CrossRefPubMed

43.

Camlin CS, Koss CA, Getahun M, Owino L, Itiakorit H, Akatukwasa C, et al. Understanding Demand for PrEP and Early Experiences of PrEP Use Among Young Adults in Rural Kenya and Uganda: A Qualitative Study. AIDS Behav. 2020;24:2149–62. https://doi.org/10.1007/s10461-020-02780-x.CrossRefPubMedPubMedCentral

44.

Van Der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26:13–9. https://doi.org/10.1097/QAD.0b013e3283522272.CrossRef

45.

Namey E, Agot K, Ahmed K, Odhiambo J, Skhosana J, GuestG and CA. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk- reduction counselling. Cult Heal. Sex. 2016;18:1081–91. https://doi.org/10.1080/13691058.2016.1164899.

46.

Eakle R, Weatherburn P, Bourne A. Understanding user perspectives of and preferences for oral PrEP for HIV prevention in the context of intervention scale-up: a synthesis of evidence from sub-Saharan Africa. J Int AIDS Soc. 2019;22:30–9. https://doi.org/10.1002/jia2.25306.CrossRef

47.

Rousseau E, Katz AWK, O’Rourke S, Bekker LG, Delany-Moretlwe S, Bukusi E, et al. Adolescent girls and young women’s PrEP-user journey during an implementation science study in South Africa and Kenya. PLoS One2021;16. https://doi.org/10.1371/journal.pone.0258542.

48.

What’s the 2+1+1? event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: update to WHO’S recommendation on oral PREP. Tech. Br.https://apps.who.int/iris/bitstream/handle/10665/325955/WHO-CDS-HIV-19.8-eng.pdf?ua=1.

49.

Scherf KS, Behrmann M, Dahl RE. Facing changes and changing faces in adolescence: A new model for investigating adolescent-specific interactions between pubertal, brain and behavioral development. Dev Cogn Neurosci. 2012;2:199–219. https://doi.org/10.1016/j.dcn.2011.07.016.CrossRefPubMed

50.

Romer D. Adolescent Risk Taking, Impulsivity, and Brain Development: Implications for Prevention. Dev. Psychobiol.2010;263–76. https://doi.org/10.1002/dev.20442.

51.

Spear LP. Adolescent Neurodevelopment Linda. J Adolesc Heal.2013;23:1–7. https://doi.org/10.1016/j.jadohealth.2012.05.006.

52.

Celum CL, Gill K, Morton JF, Stein G, Myers L, Thomas KK, et al. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. J. Int. AIDS Soc.2020;23. https://onlinelibrary.wiley.com/doi/https://doi.org/10.1002/jia2.25636.

53.

Thrasher AD, Earp JAL, Golin CE, Zimmer CR. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49:84–93. https://doi.org/10.1097/QAI.0b013e3181845589.CrossRefPubMed

54.

Ward H, Garnett GP, Mayer KH, Dallabetta GA. Maximizing the impact of HIV prevention technologies in sub-Saharan Africa. J. Int. AIDS Soc.2019;22. https://doi.org/10.1002/jia2.25319.

Title: Trust in the provider and accurate self-reported PrEP adherence among adolescent girls and young women in South Africa and Zimbabwe: HPTN 082 study
Authors: Geetha Beauchamp
Deborah Donnell
Sybil Hosek
Peter L. Anderson
Kwun C. G. Chan
Bonnie J. Dye
Nyaradzo Mgodi
Linda-Gail Bekker
Sinead Delany-Moretlwe
Connie Celum
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Tenofovir
Human Immunodeficiency Virus
Biomarkers
Published in: BMC Women's Health / Issue 1/2023
Electronic ISSN: 1472-6874
DOI: https://doi.org/10.1186/s12905-023-02418-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Trust in the provider and accurate self-reported PrEP adherence among adolescent girls and young women in South Africa and Zimbabwe: HPTN 082 study

Abstract

Background

Methods

Results

Conclusion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2023

Chronic conditions in women: the development of a National Institutes of health framework

Sexual and reproductive health and gender-based violence among female migrants in Morocco: a cross sectional survey

Comparative diagnostic accuracy of the IOTA SRR and LR2 scoring systems for discriminating between malignant and Benign Adnexal masses by junior physicians in Chinese patients: a retrospective observational study

The relation between obesity and breast cancer risk in women by considering menstruation status and geographical variations: a systematic review and meta-analysis

Correction to: Human immunodeficiency virus epidemic scenery among brazilian women: a spatial analysis study

Modern contraception utilization and associated factors among all women aged 15–49 in Ethiopia: evidence from the 2019 Ethiopian Mini Demographic and Health Survey